Concern topic
Endocrine-active
What this topic is
This topic collects ingredient-level rows our method links to the body-system activity covered by the linked method category. The hub is scoped to cited ingredient evidence and does not turn a source row into a product-level conclusion.
By NordicScan Evidence Engine · assembled from structured ingredient evidence records · source spans verified by automated gates · Reviewed 2026-07-08 · Evidence snapshot geo-wave1-evidence-snapshot-2026-07-08 · Scoring engine det_v3 · how we score.
Ingredients our method links to this topic
EU SCCS / European Commission: In the EU, BHA is flagged by the SCCS in opinion SCCS/1682/25 (adopted 26 March 2026) reviewing potential endocrine activity in dermal cosmetic use at in-use concentrations.
ParabensEU SCCS: The EU SCCS flagged by review certain parabens for potential endocrine activity, which informed the EU concentration limits; longer-chain parabens carried the greatest uncertainty. US FDA: The US FDA flagged parabens for continued review: it states parabens are used as cosmetic preservatives, that cosmetic ingredients (other than color additives) do not require FDA pre-market approval, and that it continues to evaluate published data on their potential endocrine effects; no US concentration cap is set.
Read the category method page for scope, evidence tiers, and the words our method uses.
Common questions
- Why do cosmetic rows appear here?
- Some current snapshot rows are route-specific cosmetic rows, so the card keeps that scope and links to the ingredient page.
- Does the hub add extra interpretation?
- No. The card line is copied from an already-gated ingredient evidence row with its authority attribution.
Reviewed 2026-07-08 · Evidence snapshot geo-wave1-evidence-snapshot-2026-07-08 · Scoring engine det_v3 · All concern topics.